Hpv-Associated Cancer
Triple-combination therapy extends survival in HPV-positive cancers
A triple-therapy combination extended OS compared with historical data among certain patients with advanced HPV-positive cancers, according to one of the agent’s manufacturers.
Decrease in cervical cancer rates may be linked to HPV screening, vaccination
A decrease in cervical cancer rates in the United States, most notably among younger women, may be associated with HPV vaccination approval, according to a retrospective, cross-sectional study published in JAMA Network Open.
FDA clears INDs for cell therapies to treat multiple cancer types
The FDA cleared investigational new drug applications for three cell therapies in development for oncology indications.
Increased epigenetic age acceleration observed among patients with head and neck cancer
Patients with head and neck cancer experienced an increase in epigenetic age acceleration, especially directly after treatment, which appeared associated with greater fatigue and inflammation, according to a study in Cancer.
Cervical cancer incidence declines as rates of other HPV-associated cancers rise
Incidence of cervical cancer declined as rates of other HPV-associated cancers increased significantly in the U.S. from 2001 to 2017, according to a population-based study of trends presented during the virtual ASCO Annual Meeting.
Should HPV self-testing be usual care in the US?
Self-sampling for HPV infection to screen for cervical cancer prevention would be a useful option for many at-risk individuals as an alternative to provider-collected HPV and cervical cytology.
HPV vaccination substantially reduces risk for invasive cervical cancer
Quadrivalent HPV vaccination substantially reduced the risk for invasive cervical cancer among Swedish girls and women aged 10 to 30 years, according to results of a study published in The New England Journal of Medicine.
American Cancer Society recommends routine HPV vaccination starting at age 9 years
Health care providers should begin offering routine HPV vaccination to children as young as age 9 years in order to increase rates of on-time administration, according to an updated American Cancer Society guideline.
FDA expands Gardasil 9 approval for head and neck cancer prevention
The FDA expanded the indication of HPV 9-valent vaccine, recombinant to include prevention of oropharyngeal and other head and neck cancers caused by HPV types 16, 18, 31, 33, 45, 52 and 58, according to a manufacturer-issued press release.
Low-dose radiation after transoral resection effective in HPV-related oropharynx cancer
Transoral resection followed by low-dose radiation appeared safe and effective for patients with p16-positive oropharynx cancer, according to results of a randomized phase 2 trial presented during the ASCO20 Virtual Scientific Program.